Methods of analysis of blood from deceased donors

Abstract

The invention provides cellular compositions that contain CD34+ cells derived from bone marrow of a decease donor and CD3+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.

What is claimed is: 
     
         1 . A method of assessing whether blood derived from a deceased donor is suitable for use in manufacture of a product to administer to a living recipient, the method comprising:
 obtaining blood from a deceased donor;   analyzing a component of the blood; and   determining, based on analysis of the component, whether the blood is suitable for use in manufacture of a product to administer to a living recipient.   
     
     
         2 . The method of  claim 1 , wherein the component comprises T cells. 
     
     
         3 . The method of  claim 2 , wherein the analyzing step comprises analyzing T cell activation, T cell exhaustion, T cell anergy, T cell proliferation, T cell viability, or T cell apoptosis. 
     
     
         4 . The method of  claim 1 , wherein the component comprises hematopoietic stem and progenitor cells (HSPCs). 
     
     
         5 . The method of  claim 4 , wherein the analyzing step comprises analyzing HSPC proliferation, HSPC viability, or HSPC apoptosis. 
     
     
         6 . The method of  claim 1 , wherein the component comprises a non-cellular component. 
     
     
         7 . The method of  claim 6 , wherein the non-cellular component comprises a cytokine or chemokine. 
     
     
         8 . The method of  claim 1 , further comprising:
 using material from the blood in the manufacture of the product if the blood is determined to be suitable for such use.   
     
     
         9 . The method of  claim 8 , wherein the material comprises T cells. 
     
     
         10 . The method of  claim 8 , wherein the material comprises HSPCs. 
     
     
         11 . A method of assessing whether blood derived from a deceased donor is suitable for use in manufacture of a product to administer to a living recipient, the method comprising:
 obtaining blood from a deceased donor;   analyzing a component of a non-blood tissue from the deceased donor; and   determining, based on analysis of the component, whether the blood is suitable for use in manufacture of a product to administer to a living recipient.   
     
     
         12 . The method of  claim 11 , wherein the component comprises T cells. 
     
     
         13 . The method of  claim 12 , wherein the analyzing step comprises analyzing T cell activation, T cell exhaustion, and T cell anergy. 
     
     
         14 . The method of  claim 11 , wherein the component comprises a non-cellular component. 
     
     
         15 . The method of  claim 14 , wherein the non-cellular component comprises a cytokine or chemokine. 
     
     
         16 . The method of  claim 11 , wherein the non-blood tissue comprises bone marrow. 
     
     
         17 . The method of  claim 11 , further comprising:
 analyzing a second component, the second component being a component of the blood, wherein the determining step is also based on analysis of the second component.   
     
     
         18 . The method of  claim 11 , further comprising:
 using material from the blood in the manufacture of the product if the blood is determined to be suitable for such use.   
     
     
         19 . The method of  claim 18 , wherein the material comprises T cells. 
     
     
         20 . The method of  claim 18 , wherein the material comprises HSPCs.